This clinical trial is focused on studying Thyroid Eye Disease (TED), a condition often associated with autoimmune thyroid disorders like Graves’ disease or Hashimoto’s thyroiditis. The study will evaluate a treatment called Efgartigimod, which is administered as a solution for injection using a pre-filled syringe. Efgartigimod is a type of protein designed to interact with the immune system, specifically targeting a receptor known as FcRn. The trial will compare the effects of Efgartigimod with a placebo to understand its effectiveness and safety.
The purpose of the study is to assess how well Efgartigimod works in reducing symptoms of Thyroid Eye Disease, particularly focusing on the reduction of eye bulging, known as proptosis, over a 24-week period. Participants in the study will receive either Efgartigimod or a placebo through subcutaneous injections, which means the injection is given under the skin. The study will monitor changes in eye symptoms and overall quality of life during this time.
Participants will be adults diagnosed with active, moderate-to-severe Thyroid Eye Disease. The study will involve regular visits to monitor the effects of the treatment and ensure the safety and well-being of the participants. The trial aims to provide valuable information on whether Efgartigimod can be a beneficial treatment option for those affected by this condition.
Belgium 
Bulgaria 
Czechia 
Estonia 
Germany 
Greece 
Hungary 
Italy 
Romania 
Spain 